Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study

Area of Science:

• Neuroscience
• Genetics
• Epidemiology

Background:

• Apolipoprotein E epsilon4 (apoE ε4) is linked to familial and sporadic Alzheimer's disease (AD).
• The age-specific risk of apoE ε4 for AD in the general elderly population remains unclear.

Purpose of the Study:

• To investigate the association between apoE ε4 and the risk of developing AD and other dementias in an elderly, population-based cohort.
• To establish the age-associated risk of apoE ε4 for dementia.

Main Methods:

• Population-based Framingham Study cohort.
• 1,030 participants aged 71–100 years.
• Kaplan-Meier survival analysis and risk ratio calculations for AD and other dementias based on apoE genotype.

Main Results:

• Homozygous apoE ε4/ε4 individuals had a 30.1-fold increased risk for AD compared to non-carriers.
• Heterozygous apoE ε3/ε4 individuals had a 3.7-fold increased risk for AD.
• ApoE ε4 was also associated with increased risk for non-AD dementias, primarily multi-infarct dementia and stroke.
• ApoE ε2 genotype was associated with absence of AD.
• Most apoE ε4 carriers did not develop dementia; half of AD cases were not associated with apoE ε4.
• Low positive predictive value (0.10) for apoE genotyping as an AD screening test.

Conclusions:

• Apolipoprotein E epsilon4 is a potent risk factor for AD and potentially other dementias in the elderly.
• Despite increased risk, most apoE ε4 carriers do not develop dementia, limiting its utility as a standalone screening tool.
• ApoE genotyping is not supported as a screening test for Alzheimer's disease due to its low positive predictive value.